The Fibrinolytic Status in Liver Diseases

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 5, 2015, Pages 474-480

  Leebeek, Frank W G ^a   Rijken, Dingeman C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

acute liver failure; cirrhosis; fibrinolysis; liver; plasminogen activator; 2 antiplasmin

Indexed keywords

FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR;

ACUTE LIVER FAILURE; ARTICLE; BLOOD CLOT LYSIS; BLOOD LEVEL; CONTROLLED STUDY; END STAGE LIVER DISEASE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; PLASMA; PRIORITY JOURNAL; TURBIDIMETRY; BLOOD; PATHOLOGY; PHYSIOLOGY;

FIBRINOLYSIS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER FAILURE, ACUTE; PLASMINOGEN ACTIVATORS;

EID: 84937812371     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1550437     Document Type: Article

References (65)

1. Rijken D. C., Lijnen H. R. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost: 2009; 7 1 4 13
2. Rijken D. C., Wijngaards G., Welbergen J. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med: 1981; 97 4 477 486
3. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem: 1982; 257 6 2912 2919
4. Declerck P. J., Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost: 2013; 39 4 356 364
5. Aoki N. The past, present and future of plasmin inhibitor. Thromb Res: 2005; 116 6 455 464
6. Nesheim M., Bajzar L. The discovery of TAFI. J Thromb Haemost: 2005; 3 10 2139 2146
7. Sakharov D. V., Plow E. F., Rijken D. C. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem: 1997; 272 22 14477 14482
8. Kooistra T., Schrauwen Y., Arts J., Emeis J. J. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol: 1994; 59 4 233 255
9. Knipe L., Meli A., Hewlett L., et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood: 2010; 116 12 2183 2191
10. Binder B. R., Christ G., Gruber F., et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci: 2002; 17 56 61
11. Otter M., Kuiper J., van Berkel T. J., Rijken D. C. Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver. Ann N Y Acad Sci: 1992; 667 431 442
12. Narita M., Bu G., Herz J., Schwartz A. L. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J Clin Invest: 1995; 96 2 1164 1168
13. Mayer E. J., Fujita T., Gardell S. J., Shebuski R. J., Reilly C. F. The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit. Blood: 1990; 76 8 1514 1520
14. Horn I. R., van den Berg B. M., Moestrup S. K., Pannekoek H., van Zonneveld A. J. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator. Thromb Haemost: 1998; 80 5 822 828
15. Hu L., Bovenschen N., Havekes L. M., van Vlijmen B. J., Tamsma J. T. Plasma plasminogen activator inhibitor-1 level is not regulated by the hepatic low-density lipoprotein receptor-related protein. J Thromb Haemost: 2007; 5 11 2301 2304
16. Pepperell D., Morel-Kopp M. C., Ward C. Clinical application of fibrinolytic assays. In: Kolev K., ed. Fibrinolysis and Thrombolysis. Rijeka, Croatia InTech: 2014; 125 162
17. Lisman T., de Groot P. G., Meijers J. C., Rosendaal F. R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood: 2005; 105 3 1102 1105
18. Talens S., Malfliet J. J., RudeŽ G., et al. Biological variation in tPA-induced plasma clot lysis time. Thromb Haemost: 2012; 108 4 640 646
19. He S., Zhu K., Skeppholm M., et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost: 2007; 98 4 871 882
20. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie; einem neuen Untersuchungsverfahren. Klin Wochenschr: 1948; 26 37-38 577 583
21. Raza I., Davenport R., Rourke C., et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost: 2013; 11 2 307 314
22. Rijken D. C., Hoegee-de Nobel E., Jie A. F., Atsma D. E., Schalij M. J., Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost: 2008; 6 1 151 157
23. Amiral J., Malmejac A., Gin H., et al. Evaluation of the fibrinolytic potential on plasma: physiological and pathological variations, and associations with cardio-vascular disease risk factors. Fibrinolysis Proteol.: 1999; 13 1 1 10
24. Goodpasture E. Fibrinolysis in chronic hepatic insufficiency. Bull Johns Hopkins Hosp: 1914; 25 285 330 336
25. Ratnoff O. D. Studies on a proteolytic enzyme in human plasma; the rate of lysis of plasma clots in normal and diseased individuals, with particular reference to hepatic diseases. Bull Johns Hopkins Hosp: 1949; 84 1 29 42
26. Kwaan H. C., McFadzean A. J., Cook J. Plasma fibrinolytic activity in cirrhosis of the liver. Lancet: 1956; 270 6908 132 136
27. van de Loo J., Schmiesing G. Factors of the fibrinolytic system in liver diseases [in German]. Thromb Diath Haemorrh: 1965; 14 3-4 580 591
28. Tytgat G., Collen D., De Vreker R., Verstraete M. Investigations on the fibrinolytic system in liver cirrhosis. Acta Haematol: 1968; 40 5 265 274
29. Brakman P., Mohler E. R., Astrup T. Blood fibrinolysis in liver disease. Haemostasis: 1974; 2 209 213
30. Fletcher A. P., Biederman O., Moore D., Alkjaersig N., Sherry S. Abnormal plasminogen-plasmin system activity (fibrinolysis) in patients with hepatic cirrhosis: its cause and consequences. J Clin Invest: 1964; 43 681 695
31. Das P. C., Cash J. D. Fibrinolysis at rest and after exercise in hepatic cirrhosis. Br J Haematol: 1969; 17 5 431 443
32. Francis R. B. Jr, Feinstein D. I. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis: 1984; 14 6 460 465
33. Hu K. Q., Yu A. S., Tiyyagura L., Redeker A. G., Reynolds T. B. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol: 2001; 96 5 1581 1586
34. Leebeek F. W., Kluft C., Knot E. A., de Maat M. P., Wilson J. H. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology: 1991; 101 5 1382 1390
35. Aoki N., Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta: 1978; 84 1-2 99 105
36. van Wersch J. W., Russel M. G., Lustermans F. A. The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis. Eur J Clin Chem Clin Biochem: 1992; 30 5 275 279
37. Booth N. A., Anderson J. A., Bennett B. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol: 1984; 37 7 772 777
38. Leiper K., Croll A., Booth N. A., Moore N. R., Sinclair T., Bennett B. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease. J Clin Pathol: 1994; 47 3 214 217
39. Leebeek F. WG, Kluft C., Knot E. AR, De Maat M. PM. Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med: 1989; 113 4 493 497
40. Colucci M., Binetti B. M., Branca M. G., et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology: 2003; 38 1 230 237
41. Lisman T., Leebeek F. W., Mosnier L. O., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology: 2001; 121 1 131 139
42. Tran-Thang C., Fasel-Felley J., Pralong G., Hofstetter J. R., Bachmann F., Kruithof E. K. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost: 1989; 62 2 651 653
43. Violi F., Ferro D., Basili S., et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. Hepatology: 1993; 17 1 78 83
44. Hersch S. L., Kunelis T., Francis R. B. Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood: 1987; 69 5 1315 1319
45. vanDeWater L., Carr J. M., Aronson D., McDonagh J. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood: 1986; 67 5 1468 1473
46. Bakker C. M., Knot E. A., Stibbe J., Wilson J. H. Disseminated intravascular coagulation in liver cirrhosis. J Hepatol: 1992; 15 3 330 335
47. Violi F., Ferro D., Basili S., et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology: 1995; 109 2 531 539
48. Papatheodoridis G. V., Patch D., Webster G. J., Brooker J., Barnes E., Burroughs A. K. Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography. Hepatology: 1999; 29 4 1085 1090
49. Roullet S., Freyburger G., Labrouche S., et al. Hyperfibrinolysis during liver transplantation is associated with bleeding. Thromb Haemost: 2015; 113 5 1145 1148
50. Jairath V., Hall D., Harrison P., et al. Rotational thromboelastometry in cirrhosis: hypercoagulable and hyperfibrinolytic. Gut: 2012; 61 A30
51. Stravitz R. T. Potential applications of thromboelastography in patients with acute and chronic liver disease. Gastroenterol Hepatol (N Y): 2012; 8 8 513 520
52. Kleinegris M. C., Bos M. H., Roest M., et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost: 2014; 12 10 1647 1657
53. Lisman T., Porte R. J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood: 2010; 116 6 878 885
54. Rijken D. C., Kock E. L., Guimarães A. H., et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost: 2012; 10 10 2116 2122
55. Aytac S., Turkay C., Bavbek N., Kosar A. Hemostasis and global fibrinolytic capacity in chronic liver disease. Blood Coagul Fibrinolysis: 2007; 18 7 623 626
56. Caldwell S. H., Hoffman M., Lisman T., et al. Coagulation in Liver Disease Group. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology: 2006; 44 4 1039 1046
57. Boks A. L., Brommer E. J., Schalm S. W., Van Vliet H. H. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology: 1986; 6 1 79 86
58. Violi F., Ferro D., Basili S., et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology: 1992; 15 4 672 676
59. Violi F., Ferro D., Basili S., et al. CALC Group. Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients. Hepatology: 1995; 22 1 96 100
60. Piscaglia F., Siringo S., Hermida R. C., et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology: 2000; 31 2 349 357
61. Andreotti F., Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int: 1991; 8 5 336 351
62. Violi F., Ferro D. Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis. Semin Thromb Hemost: 2013; 39 4 426 433
63. Lisman T., Bakhtiari K., Adelmeijer J., Meijers J. C., Porte R. J., Stravitz R. T. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. J Thromb Haemost: 2012; 10 7 1312 1319
64. Porte R. J., Knot E. A., Bontempo F. A. Hemostasis in liver transplantation. Gastroenterology: 1989; 97 2 488 501
65. Segal H., Cottam S., Potter D., Hunt B. J. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology: 1997; 25 3 683 688